BioSante Pharmaceuticals, Inc. To Present at BioCentury and BIO Healthcare Conferences

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, BioSante’s president & CEO will present at two healthcare conferences in October. Mr. Simes will speak at the BioCentury NewsMakers in the Biotech Industry on Friday, October 21 at 11:30 am EDT in New York and at the BIO Investor Forum on Tuesday, October 25 at 3:30 pm PDT in San Francisco.

BioSante will provide a company overview at each conference, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.

A live audio webcast of remarks by Mr. Simes, at the BioCentury conference may be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BPAX&item_id=4209619. A live audio webcast of remarks by Mr. Simes, at BIO Investor Forum may be accessed at http://www.veracast.com/webcasts/bio/investorforum2011/16113461.cfm. Both webcasts will be archived for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.



CONTACT:

For Investors:
The Trout Group LLC
Tricia Swanson, (646) 378-2953
[email protected]
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, (312) 506-5220
[email protected]

KEYWORDS:   United States  North America  California  Illinois  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.